Author:
Jiang Yan,Luo Baolin,Chen Yaqin,Peng Yanchun,Lu Wen,Chen Liangwan,Lin Yanjuan
Abstract
AbstractThe purpose of this study was to investigate the relationship between Inflammatory Prognostic Index (IPI) levels and Contrast-Induced Nephropathy (CIN) risk and postoperative clinical outcomes in patients undergoing coronary angiography (CAG) and/or percutaneous coronary intervention (PCI). A total of 3,340 consecutive patients who underwent CAG and/or PCI between May 2017 and December 2022 were enrolled in this study. Based on their baseline IPI levels, patients were categorized into four groups. Clinical characteristics and postoperative outcomes were compared among these groups. In-hospital outcomes focused on CIN risk, repeated revascularization, major bleeding, and major adverse cardiovascular events (MACEs), while the long-term outcome examined the all-cause readmission rate. Quartile analysis found a significant link between IPI levels and CIN risk, notably in the highest quartile (P < 0.001). Even after adjusting for baseline factors, this association remained significant, with an adjusted Odds Ratio (aOR) of 2.33 (95%CI 1.50–3.64; P = 0.001). Notably, baseline IPI level emerged as an independent predictor of severe arrhythmia, with aOR of 0.50 (95%CI 0.35–0.69; P < 0.001), particularly driven by the highest quartile. Furthermore, a significant correlation between IPI and acute myocardial infarction was observed (P < 0.001), which remained significant post-adjustment. For patients undergoing CAG and/or PCI, baseline IPI levels can independently predict clinical prognosis. As a comprehensive inflammation indicator, IPI effectively identifies high-risk patients post-procedure. This study underscores IPI's potential to assist medical professionals in making more precise clinical decisions, ultimately reducing mortality and readmission rates linked to cardiovascular disease (CVD).
Funder
Fujian Provincial Center for Cardiovascular Medicine
Publisher
Springer Science and Business Media LLC
Reference49 articles.
1. The Writing Committee of the Report on Cardiovascular Health Diseases in China. Interpretation of Report on Cardiovascular Health and Diseases in China 2022. Chin. J. Cardiovasc. Med. 2023, 28(04):297–312.
2. Zhou, M. et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 394(10204), 1145–1158 (2019).
3. Testa, L. et al. Unprotected left main revascularization: Percutaneous coronary intervention versus coronary artery bypass. An updated systematicreview and meta-analysis of randomised controlled trials. PLoS One. 12(6), e0179060 (2017).
4. Patel, K. V., Pandey, A. & de Lemos, J. A. Conceptual framework for addressing residual atherosclerotic cardiovascular disease risk in the era of precision medicine. Circulation. 137(24), 2551–2553 (2018).
5. Zuo, T. et al. Hyperuricemia and contrast-induced acute kidney injury: A systematic review and meta-analysis. Int. J. Cardiol. 224, 286–294 (2016).